Assessment of safety of niraparib maintenance therapy in epithelial ovarian cancer: an updated systematic review and meta-analysis of randomized control trials
There is a need to emphasize on cautious use, hematological toxicities, and personalized dosage regimens of niraparib for improved patient compliance.
Authors
- Obaid Ansari
- Usama Abdul Ahad Memon (ORCID: https://orcid.org/0000-0003-2654-6944)
- Kanza Farhan (ORCID: https://orcid.org/0009-0002-6211-7522)
- Dua Khalid
- Muhammad Saad Khan (ORCID: https://orcid.org/0009-0002-4228-6476)
- Momina Khalid (ORCID: https://orcid.org/0009-0001-3413-2752)
- Aminath Waafira (ORCID: https://orcid.org/0009-0000-3283-1982)
- Harshika Khaim Chandani (ORCID: https://orcid.org/0009-0001-0191-1573)
- Devya Khaim Chandani
Institutions
- Jinnah Sindh Medical University (PK)
- Shaheed Mohtarma Benazir Bhutto Medical University (PK)
- Maldives National University (MV)
Publication Details
- Journal
- Annals of Medicine and Surgery
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1097/ms9.0000000000003186
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05